吉妥珠单抗-奥佐格米星治疗急性粒细胞白血病的疗效——它适用于所有CD33+疾病患者吗？

Advances in cell and gene therapy Pub Date : 2018-09-24 DOI:10.1002/acg2.21

Prajwal Boddu, Farhad Ravandi

{"title":"吉妥珠单抗-奥佐格米星治疗急性粒细胞白血病的疗效——它适用于所有CD33+疾病患者吗？","authors":"Prajwal Boddu, Farhad Ravandi","doi":"10.1002/acg2.21","DOIUrl":null,"url":null,"abstract":"<p>Mechanism of action of GO in AML</p><p>Illustrator credit: Claudia Bentley\n\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>\n </p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":"1 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.21","citationCount":"0","resultStr":"{\"title\":\"Return of gemtuzumab ozogamicin in acute myeloid leukemia—Is it for everyone with CD33+ disease?\",\"authors\":\"Prajwal Boddu, Farhad Ravandi\",\"doi\":\"10.1002/acg2.21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Mechanism of action of GO in AML</p><p>Illustrator credit: Claudia Bentley\\n\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure>\\n </p>\",\"PeriodicalId\":72084,\"journal\":{\"name\":\"Advances in cell and gene therapy\",\"volume\":\"1 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/acg2.21\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in cell and gene therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/acg2.21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cell and gene therapy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acg2.21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

白血病细胞具有异常的免疫表型特征，如跨谱系标记异常、异常标记水平模式和新的表面标记表达，这有助于它们与正常造血前体细胞的区别。急性髓性白血病(AML)干细胞的静止特性使它们对常规细胞毒性具有相对的抵抗力。在这种情况下，异常表面标记物被用于开发选择性靶向AML白血病干细胞(LSCs)的治疗方案。在白血病母细胞的差异表达簇分化(CD)抗原中，CD33和CD123是基于单克隆抗体的AML治疗中更广泛利用的临床靶点。这些单克隆抗体可能通过多种机制发挥其抗AML肿瘤的作用，包括抗体介导的中和、偶联抗体的毒性载荷递送、抗体依赖的细胞毒性、补体介导的细胞毒性、抗体依赖的细胞介导的吞噬，以及通过增加T细胞和肿瘤与双特异性T细胞结合抗体的相互作用来增强T细胞抗肿瘤的功效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Return of gemtuzumab ozogamicin in acute myeloid leukemia—Is it for everyone with CD33+ disease?